Company intelligence / Profile preview

REVIAN

Morrisville, North Carolina, United Statesrevian.com ↗

Ownership: Private
Development stage: Commercial

Overview

The REVIAN Red Hair Growth System has demonstrated clinical efficacy in double-blind, placebo-controlled studies for androgenetic alopecia. It uses patented dual-wavelength LED light to stimulate nitric oxide production and inhibit DHT. Clinical trials have shown it to be an effective alternative to chemical-based topicals and prescription drugs for hair regrowth. The system has been included in multimodal treatment protocols and has published positive outcomes for both male and female pattern baldness as well as central centrifugal cicatricial alopecia.

Therapeutic areas: Dermatology
Modalities: DeviceNon-pharmacological therapy (specifically Low-Level Light Therapy / Phototherapy)
Industry: Therapeutic Medical Devices

Partnerships

None specifically named; broad partnerships with dermatology healthcare providers (>2000 US medical providers refer or use the product)

Beyond the preview

Go deeper on REVIAN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REVIAN.

Explore the full profile